Evaluation of the prognostic role of tumor cell podoplanin expression in locally advanced squamous cell carcinoma of the head and neck

Stefan Huttenlocher; Nina D. Seibold; Maximilian P. Gebhard; Frank Noack; Christoph Thorns; Katrin Hasselbacher; Barbara Wollenberg; Steven E. Schild; Dirk Rades

doi:10.1007/s00066-014-0694-1

Evaluation of the prognostic role of tumor cell podoplanin expression in locally advanced squamous cell carcinoma of the head and neck

Translated title of the contribution: Evaluation of the prognostic role of tumor cell podoplanin expression in locally advanced squamous cell carcinoma of the head and neck

Stefan Huttenlocher
, Nina D. Seibold
, Maximilian P. Gebhard
, Frank Noack
, Christoph Thorns
, Katrin Hasselbacher
, Barbara Wollenberg
, Steven E. Schild
, Dirk Rades

University of Lübeck
Mayo Clinic Scottsdale-Phoenix, Arizona

Research output: Contribution to journal › Article › peer-review

5 Scopus citations

Abstract

Conclusion: Treatment outcomes were significantly associated with performance status, pre-RT hemoglobin level, tumor site and tumor stage. Tumor cell expression of podoplanin ≤ 10 % showed a trend towards improved OS when compared to podoplanin expression of > 10 %.

Results: In multivariate analysis, ECOG performance status 0–1 (risk ratio, RR: 3.01; 95 % confidence interval, CI: 1.42–7.14; p = 0.003), pre-RT hemoglobin levels ≥ 7.45 mmol/l (12 g/dl; RR: 2.03; 95 % CI: 1.04–3.94; p = 0.038), oropharyngeal cancer (RR: 1.25; 95 % CI: 1.01–1.55; p = 0.038) and T category T1–2 (RR: 1.81; 95 % CI: 1.24–2.79; p = 0.002) were significantly associated with improved LRC. T category T1–2 (RR: 1.90; 95 % CI: 1.25–3.06; p = 0.002) and N category N0–2a (RR: 5.22; 95 % CI: 1.96–18.09; p < 0.001) were significantly associated with better MFS. Pre-RT hemoglobin levels ≥ 7.45 mmol/l (RR: 2.44; 95 % CI: 1.27–4.74; p = 0.007), T category T1–2 (RR: 1.97; 95 % CI: 1.36–3.04; p < 0.001) and N category N0–2a (RR: 2.87; 95 % CI: 1.37–6.61; p = 0.005) were significantly associated with improved OS. Podoplanin expression ≤ 10 % showed a trend towards improved OS on both univariate (p = 0.050) and multivariate analysis (RR: 1.86; 95 % CI: 0.96–3.59; p = 0.07).

Materials and methods: Podoplanin expression (≤10 % versus > 10 %) and 12 other factors were evaluated in 160 patients for their association with locoregional control (LRC), metastases-free (MFS) and overall survival (OS). Other factors were age, gender, Eastern Cooperative Oncology Group (ECOG) performance status, preradiotherapy (pre-RT) hemoglobin level, tumor site, histological grading, T category, N category, American Joint Committee on Cancer (AJCC) stage, human papillomavirus (HPV) status, extent of resection and concurrent chemotherapy.

Background and purpose: To investigate the potential prognostic role of tumor cell podoplanin expression in patients treated with resection followed by irradiation or chemoradiotherapy for locally advanced squamous cell carcinoma of the head and neck (SCCHN).

Translated title of the contribution	Evaluation of the prognostic role of tumor cell podoplanin expression in locally advanced squamous cell carcinoma of the head and neck
Original language	English
Pages (from-to)	1021-1027
Number of pages	7
Journal	Strahlentherapie und Onkologie
Volume	190
Issue number	11
DOIs	https://doi.org/10.1007/s00066-014-0694-1
State	Published - Oct 2014
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Chemoradiotherapy
Head and neck cancer
Radiotherapy
Resection
Survival

Access to Document

10.1007/s00066-014-0694-1

Cite this

Huttenlocher, S., Seibold, N. D., Gebhard, M. P., Noack, F., Thorns, C., Hasselbacher, K., Wollenberg, B., Schild, S. E., & Rades, D. (2014). Evaluation of the prognostic role of tumor cell podoplanin expression in locally advanced squamous cell carcinoma of the head and neck. Strahlentherapie und Onkologie, 190(11), 1021-1027. https://doi.org/10.1007/s00066-014-0694-1

@article{5fdc9a3040984ea59f13818fb47f3a58,

title = "Evaluation of the prognostic role of tumor cell podoplanin expression in locally advanced squamous cell carcinoma of the head and neck",

abstract = "Conclusion: Treatment outcomes were significantly associated with performance status, pre-RT hemoglobin level, tumor site and tumor stage. Tumor cell expression of podoplanin ≤ 10 \% showed a trend towards improved OS when compared to podoplanin expression of > 10 \%.Results: In multivariate analysis, ECOG performance status 0–1 (risk ratio, RR: 3.01; 95 \% confidence interval, CI: 1.42–7.14; p = 0.003), pre-RT hemoglobin levels ≥ 7.45 mmol/l (12 g/dl; RR: 2.03; 95 \% CI: 1.04–3.94; p = 0.038), oropharyngeal cancer (RR: 1.25; 95 \% CI: 1.01–1.55; p = 0.038) and T category T1–2 (RR: 1.81; 95 \% CI: 1.24–2.79; p = 0.002) were significantly associated with improved LRC. T category T1–2 (RR: 1.90; 95 \% CI: 1.25–3.06; p = 0.002) and N category N0–2a (RR: 5.22; 95 \% CI: 1.96–18.09; p < 0.001) were significantly associated with better MFS. Pre-RT hemoglobin levels ≥ 7.45 mmol/l (RR: 2.44; 95 \% CI: 1.27–4.74; p = 0.007), T category T1–2 (RR: 1.97; 95 \% CI: 1.36–3.04; p < 0.001) and N category N0–2a (RR: 2.87; 95 \% CI: 1.37–6.61; p = 0.005) were significantly associated with improved OS. Podoplanin expression ≤ 10 \% showed a trend towards improved OS on both univariate (p = 0.050) and multivariate analysis (RR: 1.86; 95 \% CI: 0.96–3.59; p = 0.07).Materials and methods: Podoplanin expression (≤10 \% versus > 10 \%) and 12 other factors were evaluated in 160 patients for their association with locoregional control (LRC), metastases-free (MFS) and overall survival (OS). Other factors were age, gender, Eastern Cooperative Oncology Group (ECOG) performance status, preradiotherapy (pre-RT) hemoglobin level, tumor site, histological grading, T category, N category, American Joint Committee on Cancer (AJCC) stage, human papillomavirus (HPV) status, extent of resection and concurrent chemotherapy.Background and purpose: To investigate the potential prognostic role of tumor cell podoplanin expression in patients treated with resection followed by irradiation or chemoradiotherapy for locally advanced squamous cell carcinoma of the head and neck (SCCHN).",

keywords = "Chemoradiotherapy, Head and neck cancer, Radiotherapy, Resection, Survival",

author = "Stefan Huttenlocher and Seibold, \{Nina D.\} and Gebhard, \{Maximilian P.\} and Frank Noack and Christoph Thorns and Katrin Hasselbacher and Barbara Wollenberg and Schild, \{Steven E.\} and Dirk Rades",

note = "Publisher Copyright: {\textcopyright} 2014, Springer-Verlag Berlin Heidelberg.",

year = "2014",

month = oct,

doi = "10.1007/s00066-014-0694-1",

language = "English",

volume = "190",

pages = "1021--1027",

journal = "Strahlentherapie und Onkologie",

issn = "0179-7158",

publisher = "Springer Science and Business Media Deutschland GmbH",

number = "11",

}

TY - JOUR

T1 - Evaluation of the prognostic role of tumor cell podoplanin expression in locally advanced squamous cell carcinoma of the head and neck

AU - Huttenlocher, Stefan

AU - Seibold, Nina D.

AU - Gebhard, Maximilian P.

AU - Noack, Frank

AU - Thorns, Christoph

AU - Hasselbacher, Katrin

AU - Wollenberg, Barbara

AU - Schild, Steven E.

AU - Rades, Dirk

PY - 2014/10

Y1 - 2014/10

N2 - Conclusion: Treatment outcomes were significantly associated with performance status, pre-RT hemoglobin level, tumor site and tumor stage. Tumor cell expression of podoplanin ≤ 10 % showed a trend towards improved OS when compared to podoplanin expression of > 10 %.Results: In multivariate analysis, ECOG performance status 0–1 (risk ratio, RR: 3.01; 95 % confidence interval, CI: 1.42–7.14; p = 0.003), pre-RT hemoglobin levels ≥ 7.45 mmol/l (12 g/dl; RR: 2.03; 95 % CI: 1.04–3.94; p = 0.038), oropharyngeal cancer (RR: 1.25; 95 % CI: 1.01–1.55; p = 0.038) and T category T1–2 (RR: 1.81; 95 % CI: 1.24–2.79; p = 0.002) were significantly associated with improved LRC. T category T1–2 (RR: 1.90; 95 % CI: 1.25–3.06; p = 0.002) and N category N0–2a (RR: 5.22; 95 % CI: 1.96–18.09; p < 0.001) were significantly associated with better MFS. Pre-RT hemoglobin levels ≥ 7.45 mmol/l (RR: 2.44; 95 % CI: 1.27–4.74; p = 0.007), T category T1–2 (RR: 1.97; 95 % CI: 1.36–3.04; p < 0.001) and N category N0–2a (RR: 2.87; 95 % CI: 1.37–6.61; p = 0.005) were significantly associated with improved OS. Podoplanin expression ≤ 10 % showed a trend towards improved OS on both univariate (p = 0.050) and multivariate analysis (RR: 1.86; 95 % CI: 0.96–3.59; p = 0.07).Materials and methods: Podoplanin expression (≤10 % versus > 10 %) and 12 other factors were evaluated in 160 patients for their association with locoregional control (LRC), metastases-free (MFS) and overall survival (OS). Other factors were age, gender, Eastern Cooperative Oncology Group (ECOG) performance status, preradiotherapy (pre-RT) hemoglobin level, tumor site, histological grading, T category, N category, American Joint Committee on Cancer (AJCC) stage, human papillomavirus (HPV) status, extent of resection and concurrent chemotherapy.Background and purpose: To investigate the potential prognostic role of tumor cell podoplanin expression in patients treated with resection followed by irradiation or chemoradiotherapy for locally advanced squamous cell carcinoma of the head and neck (SCCHN).

AB - Conclusion: Treatment outcomes were significantly associated with performance status, pre-RT hemoglobin level, tumor site and tumor stage. Tumor cell expression of podoplanin ≤ 10 % showed a trend towards improved OS when compared to podoplanin expression of > 10 %.Results: In multivariate analysis, ECOG performance status 0–1 (risk ratio, RR: 3.01; 95 % confidence interval, CI: 1.42–7.14; p = 0.003), pre-RT hemoglobin levels ≥ 7.45 mmol/l (12 g/dl; RR: 2.03; 95 % CI: 1.04–3.94; p = 0.038), oropharyngeal cancer (RR: 1.25; 95 % CI: 1.01–1.55; p = 0.038) and T category T1–2 (RR: 1.81; 95 % CI: 1.24–2.79; p = 0.002) were significantly associated with improved LRC. T category T1–2 (RR: 1.90; 95 % CI: 1.25–3.06; p = 0.002) and N category N0–2a (RR: 5.22; 95 % CI: 1.96–18.09; p < 0.001) were significantly associated with better MFS. Pre-RT hemoglobin levels ≥ 7.45 mmol/l (RR: 2.44; 95 % CI: 1.27–4.74; p = 0.007), T category T1–2 (RR: 1.97; 95 % CI: 1.36–3.04; p < 0.001) and N category N0–2a (RR: 2.87; 95 % CI: 1.37–6.61; p = 0.005) were significantly associated with improved OS. Podoplanin expression ≤ 10 % showed a trend towards improved OS on both univariate (p = 0.050) and multivariate analysis (RR: 1.86; 95 % CI: 0.96–3.59; p = 0.07).Materials and methods: Podoplanin expression (≤10 % versus > 10 %) and 12 other factors were evaluated in 160 patients for their association with locoregional control (LRC), metastases-free (MFS) and overall survival (OS). Other factors were age, gender, Eastern Cooperative Oncology Group (ECOG) performance status, preradiotherapy (pre-RT) hemoglobin level, tumor site, histological grading, T category, N category, American Joint Committee on Cancer (AJCC) stage, human papillomavirus (HPV) status, extent of resection and concurrent chemotherapy.Background and purpose: To investigate the potential prognostic role of tumor cell podoplanin expression in patients treated with resection followed by irradiation or chemoradiotherapy for locally advanced squamous cell carcinoma of the head and neck (SCCHN).

KW - Chemoradiotherapy

KW - Head and neck cancer

KW - Radiotherapy

KW - Resection

KW - Survival

UR - https://www.scopus.com/pages/publications/84922333814

U2 - 10.1007/s00066-014-0694-1

DO - 10.1007/s00066-014-0694-1

M3 - Article

C2 - 24928249

AN - SCOPUS:84922333814

SN - 0179-7158

VL - 190

SP - 1021

EP - 1027

JO - Strahlentherapie und Onkologie

JF - Strahlentherapie und Onkologie

IS - 11

ER -

Evaluation of the prognostic role of tumor cell podoplanin expression in locally advanced squamous cell carcinoma of the head and neck

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this